Revised International Staging System for Myeloma
Classifies multiple myeloma prognosis into three stages.
When to use
Adults with newly diagnosed multiple myeloma, for prognostic stratification.
Pearls and pitfalls
- R-ISS combines ISS, LDH and high-risk cytogenetics.
- ISS stage III with elevated LDH or high-risk cytogenetics defines R-ISS III.
- ISS stage I without elevated LDH and without high-risk cytogenetics defines R-ISS I.
- Staging guides prognosis, but treatment depends on eligibility and disease biology.
Fill in the fields to see the result.
Formula
R-ISS I: ISS I without elevated LDH and without high-risk cytogenetics. R-ISS III: ISS III with elevated LDH or high-risk cytogenetics. All other cases are R-ISS II.
Evidence
Revised system derived by the International Myeloma Working Group to improve prognostic stratification of ISS.
References
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869. doi:10.1200/JCO.2015.61.2267
Frequently asked questions
What is Revised International Staging System for Myeloma?
Classifies multiple myeloma prognosis into three stages. Adults with newly diagnosed multiple myeloma, for prognostic stratification.
How is the result calculated?
R-ISS I: ISS I without elevated LDH and without high-risk cytogenetics. R-ISS III: ISS III with elevated LDH or high-risk cytogenetics. All other cases are R-ISS II.
How should the result be interpreted?
Revised system derived by the International Myeloma Working Group to improve prognostic stratification of ISS.
What are the sources?
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.